Abstract: A method for diagnosing large vessel occlusion in a subject that is suffering from an ischemic stroke episode, the method including determining the level of certain proteins in an isolated sample of a subject. A method for differentiating ischemic stroke from any other condition selected from haemorrhagic stroke, transient ischemic attack and a stroke mimicking condition. Simplified kits including reagents to carry out the methods are also disclosed.

Abstract: The invention relates to a method for selecting a patient suffering stroke for a reperfusion therapy based on determining the level of retinol binding protein-4 (RBP4) and N-terminal fragment of B-type natriuretic peptide (NT-proBNP) in an isolated sample of said patient. The invention also relates to a method of differentiating ischemic stroke from haemorrhagic stroke and to kits comprising reagents to carry out the methods.

Abstract: The present invention relates to the identification and use of diagnostic markers for ischemic stroke of the lacunar subtype. The invention relates to devices and kits for performing these methods.

Abstract: The invention relates to a brain damage diagnostic method, carried out in vitro in samples from patients suspected of suffering from such damage. The method uses the detection of the chemokine CCL23 that allows deducting further prognostic information. The invention also relates to uses of means for the detection of this chemokine with the purpose of detecting the presence of brain damage caused by stroke, brain trauma, brain tumor, Alzheimer disease.

Abstract: The invention relates to the use of endothelial progenitor cells (EPC) that comprises superparamagnetic particle aggregates which are able for the preparation of a medicament. Particular nanoparticle aggregates with a coating of compounds with net negative charge, and the method for obtaining them are also disclosed.

Abstract: The invention is a method of predicting the evolution of a patient suffering of a neurovascular disease, preferably stroke, comprising obtaining a biological sample of said patient, assessing in said biological sample the level of endostatin and FasL, determining whether said levels of endostatin and FasL together are above or below predetermined cut-off levels and predicting the functional outcome of said neurovascular disease on said patient evaluating the result of the previous step. The combination of endostatin and FasL is a more powerful predictor that any clinical prognostic tool and adds significant prognostic value to all other clinical variables of the art.

Abstract: The invention relates to a method of aiding the diagnosis of acute brain damage in a subject, said method comprising (i) assaying the concentration of at least one oxidative stress polypeptide selected from the group consisting of: PRDX1, PRDX6 and GSTP1 in a sample from said subject; and (ii) assaying the concentration of at least one further polypeptide selected from Panel A; (Hi) comparing the concentrations of (i) and (ii) to the concentrations of the polypeptides in a reference standard and determining quantitative ratios for said polypeptides; (iv) wherein a finding of a quantitative ratio of each of the assayed polypeptides in the sample to the polypeptides in the reference standard of greater than 1.3 indicates an increased likelihood of acute brain damage having occurred in said subject.

Abstract: The present invention relates to the identification and use of diagnostic markers for ischemic stroke of the lacunar subtype. The invention relates to devices and kits for performing these methods.